Physician profile
Robert I Sack
NPI 1124148721
$3,864.10
in general payments reported to CMS, 2019-2025
13 companies · $39.78 in 2025
The $39.78 reported for 2025 was less than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,403 · 2020: $421 · 2025: $39.78.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $39.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $39.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $828.63 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $568.06 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $528.11 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $481.74 | 2019 | |
| Janssen Pharmaceuticals, INC | $444.14 | 2019-2020 | |
| Allergan, INC. | $391.34 | 2019-2020 | |
| Lundbeck LLC | $267.17 | 2019-2020 | |
| Indivior INC. | $116.60 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $109.35 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.78 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $37.16 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $30.30 | 2019 | |
| Shire North American Group INC | $21.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Sack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.